Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation

Sparcl1 Exhibits Different Expression Pattern Between Left- And Right-Sided Colon Cancer And It Was Down-Regulated Via Dna Methylation

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

Abstract B20: Secreted Protein Acidic and Rich in Cysteines-Like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Abstract 2120: Secreted Protein Acidic and Rich in Cysteine, Like 1(SPARCL1), Inhibits Aggressiveness and Relates to Better Prognosis in Colorectal Cancers

Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis

SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.

The oncogenic functions of SPARCL1 in bladder cancer

Supplementary Figure 6 from <i>secreted Protein Acidic and Rich in Cysteines-like 1</i> Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Supplementary Figure 4 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.

SPARCL1 is a Novel Predictor of Tumor Recurrence and Survival in Hilar Cholangiocarcinoma

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Supplementary Figure 3 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer

Identifying liver metastasis-related hub genes in breast cancer and characterizing SPARCL1 as a potential prognostic biomarker

SPARCL1, Shp2, MSH2, E-cadherin, P53, ADCY-2 and MAPK Are Prognosis-Related in Colorectal Cancer

Role of SMC1A overexpression as a predictor of poor prognosis in late stage colorectal cancer

Aberrant methylation of secreted frizzled-related protein genes in tissues of colorectal cancer and cancer cell lines

The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway